Himanshu Jain’s Post

The 10 biggest biopharma companies have all reported Q1 results, and they earned ~$120 billion in revenue. Here is some context behind what drove the biggest increases and declines: 1. Three companies achieved growth of >20%. For Lilly and Novo, it was the continued ramp up of their GLP-1s, which are still in the early innings of their growth story. Amgen's growth was driven by its $28B acquisition of Horizon, without which growth would have been a more modest 6%. 2. Several companies continued to face lingering after-effects from Covid: Pfizer was the biggest, but J&J and Roche also had larger than usual declines thanks to Covid-product sales trailing off. Excluding the decline in Covid vaccine and Paxlovid sales, Pfizer's revenue actually grew 11%, which indicates future quarters will see more positive results. 3. AbbVie managed to keep sales flat, despite facing significant disruption to its biggest-selling medicine, Humira. Humira began to face full competition in the US last year, but strong sales increases of its other immunology medicines Skyrizi and Rinvoq enabled AbbVie to keep immunology and overall revenues essentially unchanged, showing the benefits of its years-long work to diversify its pipeline.

This is very interesting to see the growth in revenue, while seeing how some of these companies are positioning.

NEWS OF THE DAY! Unveiling Pharma's Top 3 Powerhouse Buyout Targets: A Surge in M&A Activity Signals a Game-Changing Shift   1. Phathom Pharmaceuticals (PHAT), Rhythm Pharmaceuticals Inc.(RYTM), and Vaxcyte (PCVX) are top picks for potential buyouts in the pharmaceutical industry, according to analyst Joseph Stringer from Needham. 2. Needham gave buy ratings to these companies, with price targets ranging from $26 to $95 per share. 3. Stringer predicts an increase in merger and acquisition (M&A) activity throughout 2024, particularly targeting mid-stage companies in fields like Oncology, Immunology, and Rare Disease. 4. During the first quarter of 2024, there were 13 M&A deals, surpassing the average of 8.2 quarterly deals since 2018. 5. Bayer, Roche, and Regeneron are identified as potential buyers for earlier-stage companies, while Takeda Pharmaceutical, Biogen, Bristol-Myers Squibb, and Pfizer are likely to target late-stage companies. 6. The average premiums for takeovers are showing a slight decline, with the 1-day premium averaging 73% in Q1 2024, slightly lower than the historical average of 77%. 7. Equity takeout multiples have also decreased in recent quarters, indicating a shift in the market dynamics for acquisitions. =>Please follow Finplate and stay updated with the latest #mergersandacquisitions news. Thanks in advance. To read the news in detail, click below: https://lnkd.in/gvP7UpJ4

Pfizer reported impressive Q2 results, surpassing revenue and earnings expectations, thanks to cost-cutting initiatives and strong product sales. The company raised its full-year outlook, with adjusted earnings now expected to be between $2.45 and $2.65 per share and revenue projected at $59.5 billion to $62.5 billion. Key drivers included a 76% increase in Paxlovid sales and growth in non-Covid products like Seagen's cancer treatments and Vyndaqel drugs. However, Pfizer shares fell by over 1%. #Pharmaceuticals #Earnings #RevenueGrowth #Healthcare #Biotech #Innovation #drugs #pharma #pharmacybenefitsmanagement https://lnkd.in/eEiEzRdx

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

From GLP-1-driven market upheavals to strategic acquisitions and partnerships, the last decade in biopharma has seen dramatic shifts, with industry-wide growth and fascinating contrasts among top players. #Biopharma #MarketTrends #Innovation

The numbers are in, Top 20 Pharmas by 2023 revenue. I have added current market cap info from the web as well. Interesting to compare the two numbers by company. Note Eli Lilly vs J&J, revenue is less than 50% yet market cap is 2x higher. Extraordinary market outlook. The Fierce Biotech article provides a brief synopsis of each company and current fiscal condition related to pipeline activity. * Johnson and Johnson, $85.16 Bn [market cap $366 Bn] * Roche, $65.32 Bn [ $202 Bn] * Merck, $60.1 Bn [ $320 Bn] * Pfizer, $58.5 Bn [ $147 Bn] * Abbvie, $54.3 Bn [ $286 Bn] * Sanofi, $46.6 Bn [ $118 Bn] * Astra Zeneca, $45.81 Bn [ $215 Bn] * Novartis, $45.44 Bn [ $209 Bn] * Bristol Myers Squibb, $45 Bn [ $98 bn] * GSK, $38.4 Bn [ $85 Bn] * Eli Lilly, $34.1 Bn [ $714 Bn] * Novo Nordisk, $33.7 Bn [ $433 Bn] * Takeda, $29.6 Bn [ $42 Bn] * Amgen, $28.2 Bn [ $142 Bn] * Boeringher Ingelheim, $27.8 Bn [ $130 Bn] * Gilead, $26.9 Bn [ $84 Bn] * Bayer, $26.1 Bn [ $28 Bn] * Merck KGA, $18.8 Bn [ $70 Bn] * Teva, $15.8 Bn [ $16 Bn] * Viatris, $15.4 Bn [ $13 Bn] https://lnkd.in/ex9BNEPb Disclaimer - Views expressed here are of the Author only.

LARGEST BIOPHARMA COMPSNIES MSRKET CAPITALISATION SOARING AS HIGH AS $ 4 TRILLION The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.